SmartPeptide
Start Free
Gut HealthAnimal / preclinical only

KPV

Tripeptide derivative of α-MSH studied in animal models of intestinal and skin inflammation.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Animal IBD and skin-inflammation models show anti-inflammatory effects via melanocortin pathways.

What's still experimental

Human RCTs are essentially absent. Oral vs injectable bioavailability in humans is poorly characterized.

Anecdotal / community reports

Gut-comfort and skin-clearing reports exist but are uncontrolled.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “KPV”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

How clinicians typically protocol this

Third-party reference · not our recommendation

Dosing phases, cycle lengths, and administration timing as listed in a compounding-pharmacy clinician reference guide. Shown so you can see what a real protocol looks like — and bring informed questions to a licensed clinician.

Third-party protocol referenceCompounding-pharmacy clinician protocol reference (Nov 2025)

Dose numbers, frequencies, and cycle lengths in this panel are extracted from a clinician-facing reference protocol distributed by a US-based compounding pharmacy in November 2025. SmartPeptide has paraphrased all descriptive text and adds no endorsement. Always consult a licensed clinician.

Repair

α-MSH-derived tripeptide (Lys-Pro-Val); studied for anti-inflammatory action.

Protocol phases

Typical
200–500 µgdaily
subcutaneous
Cycle length

Continue until desired outcome; no fixed cycle in the reference.

Reported side effects
Discontinue if skin irritation worsens
Reconstitution calculator Storage & reconstitution guide
Not medical advice. SmartPeptide does not prescribe, diagnose, or treat. The protocol above reproduces dose figures from a third-party clinician reference so you can see what compounding-pharmacy guidance typically looks like — it is not a recommendation for you, and it has not been validated against peer-reviewed dose-ranging trials. Many of these compounds are not FDA-approved for human use. Work with a licensed clinician familiar with peptide therapy before considering anything here.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “KPV”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets
No mechanism data indexed in ChEMBL, UniProt, or Open Targets for “KPV”. This is common for unscheduled research peptides that haven't been studied in structured target-binding assays.

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
53
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
0 total registered

Europe PMC — 205 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
416
all years
Last 5 years
194
recent activity
Open access
375
freely readable
OA share
90%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “KPV peptide” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
242,090
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China8,132 works
  • National Institutes of Health2,529 works
  • Japan Society for the Promotion of Science1,326 works
  • National Science Foundation1,131 works
  • National Key Research and Development Program of China1,079 works
  • Deutsche Forschungsgemeinschaft1,033 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 2 of 2 preprints indexed by Europe PMC.

Known risks

No human clinical safety data.

Reported side effects

Unknown in humans.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “KPV”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

No established human safety profile. Use only with clinical guidance, especially if you have autoimmune disease.

Questions for your clinician

  • Is there any human pharmacokinetic or safety data?
  • Could this interact with biologics or immunosuppressants I take?

Editorially curated references

Discussions about KPV

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all KPV discussions Native, moderated, no buying or selling